         |
Llista de les principals publicacions des
de 1998.
Revisi
l'abstract o sol.liciti una còpia de l'article (format PDF).
| Introdu¥r
paraula o frase: |
|
| |
|
| [Data] |
[Publicació] |
 |
| 2007 |
Clin Exp Immunol 147:189-96 |
|
[403 Kb]
|
|
Pauls E, Senserrich J, Bofill M, Clotet B, Este JA.
Induction of interleukins IL-6 and IL-8 by siRNA.
|
| 2007 |
AIDS. 21(2):169-178 |
|
[168 Kb]
|
|
Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, Tambussi G, Llibre JM, Martinez-Picado J, Vidal F, Fumaz CR, Clotet B; The TIBET Study Group.
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
|
| 2007 |
AIDS Res Hum Retroviruses. 23:965-971. |
|
|
|
Sirera G, Videla S, López-Blázquez R, Llatjos M, Tarrats A, Castellà E, Grane N, Alcalde C, Tural C, Rey-Joly C, Clotet B.
Evolution of Cervical Cytologic Changes among HIV-Infected Women with Normal Cytology in the HAART Era.
|
| 2007 |
Top HIV Med. 15:119-25. |
|
|
|
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the Drug Resistance Mutations in HIV-1: 2007.
|
| 2007 |
HIV Clin Trials. 8:213-20. |
|
|
|
Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E.
Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
|
| 2007 |
J Virol. Jul 25; [Epub ahead of print] |
|
|
|
Gimenez-Barcons M, Clotet B, Martinez MA.
Endoribonuclease-prepared siRNAs induce effective and specific inhibition of HIV-1 replication.
|
| 2007 |
J Acquir Immune Defic Syndr. 45:479-81. |
|
|
|
Clotet B, Negredo E, Girard PM, Youle M, Neubacher D.
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
|
| 2007 |
Lancet. 370:39-48. |
|
|
|
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
|
| 2007 |
Hepatology. Aug 1; [Epub ahead of print] |
|
|
|
Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS.
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
|
| 2007 |
J Antimicrob Chemother. 60:436-439. |
|
|
|
Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
|
| 2007 |
J Infect Dis. 196:178-80 |
|
|
|
Clotet B.
CCR5 inhibitors: promising yet challenging.
|
| 2007 |
Clin Pharmacokinet. 46:85-92 |
|
|
|
Moltó J, Valle M, Blanco A, Negredo E, DelaVarga M, Miranda C, Miranda J, Domingo P, Vilaró J, Tural C, Costa J, Barbanoj MJ, Clotet B.
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
|
| 2007 |
AIDS Patient Care STDS. 2007 Aug;21(8):533-43 |
|
|
|
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, et al
TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals.
|
| 2007 |
AIDS. 21:2033-2042 |
|
|
|
Fox ZV, Geretti AM, Kjær J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD.
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
|
| 2007 |
J Viral Hepat. 14:704-13 |
|
|
|
Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B; and the CORAL-1 study group.
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
|
| 2007 |
AIDS. 21(10):1273-81. |
|
|
|
Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
|
| 2007 |
J Virol. 81:7559-70. |
|
|
|
Izquierdo-Useros N, Blanco J, Erkizia I, Fernández-Figueras MT, Borràs FE, Naranjo-Gómez M, Bofill M, Ruiz L, Clotet B, Martinez-Picado J.
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.
|
| 2007 |
Lancet.369:1169-78. |
|
|
|
Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
|
| 2007 |
AIDS. 21:721-32. |
|
|
|
Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group.
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
|
| 2007 |
AIDS. 21:657-63. |
|
|
|
Negredo E, Martínez E, Cinquegrana D, Estany C, Clotet B.
Therapeutic management of bone demineralization in the HIV-infected population.
|
| 2007 |
J Leukoc Biol. 82:72-8. |
|
|
|
de Arquer GR, Peña R, Cabrera C, Coma G, Ruiz-Hernandez R, Guerola R, Clotet B, Ruiz L, Esté JA, Calle ML, Bofill M.
Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patients.
|
| 2007 |
Hepatology. 45:899-910. |
|
|
|
Franco S, Parera M, Aparicio E, Clotet B, Martinez MA.
Genetic and catalytic efficiency structure of an HCV protease quasispecies.
|
| 2007 |
J Virol. 81:4713-21. |
|
|
|
Villena C, Prado JG, Puertas MC, Martínez MA, Clotet B, Ruiz L, Parkin NT, Menéndez-Arias L, Martinez-Picado J.
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
|
| 2007 |
Br J Clin Pharmacol. 63:715-21. |
|
|
|
Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B.
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
|
| 2007 |
J Virol. 81:2485-96. |
|
|
|
Fernàndez G, Clotet B, Martínez MA.
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.
|
| 2007 |
AIDS Care. 19:138-45. |
|
|
|
Fumaz CR, Muñoz-Moreno JA, Ballesteros AL, Paredes R, Ferrer MJ, Salas A, Fuster D, Masmitjà E, Pérez-Alvarez N, Gómez G, Tural C, Clotet B.
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
|
| 2007 |
Mol Biol Evol 24:382-7. |
|
|
|
Parera M, Fernàndez G, Clotet B, Martínez MA.
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.
|
| 2007 |
Virus Res. 123):161-9. |
|
|
|
Franco S, Tural C, Clotet B, Martínez MA.
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.
|
| 2008 |
AIDS. 22:367-76 |
|
|
|
Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD; EuroSIDA study group.
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
|
| 2008 |
Mol Pharmacol. [Epub ahead of print] |
|
|
|
Moncunill G, Armand-Ugon M, Clotet I, Pauls E, Ballana E, Llano A, Romagnoli B, Vrijbloed JW, Gombert FO, Clotet B, De Marco S, Este JA.
Anti-HIV Activity and Resistance Profile of the CXCR4 Antagonist POL3026.
|
| 2008 |
J Acquir Immune Defic Syndr. 47:36-49 |
|
|
|
Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT.
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
|
| 2008 |
AIDS. 22:203-10 |
|
|
|
Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U.
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
|
| 2008 |
AIDS. 22:23-31 |
|
|
|
Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté JA.
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
|
| 2008 |
J Antimicrob Chemother. 61:400-4 |
|
|
|
Negredo E, Puigdomènech I, Marfil S, Puig J, Pérez-Alvarez N, Ruiz L, Rey-Joly C, Clotet B, Blanco J.
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
|
| 2008 |
Virology. 372:421-9 |
|
|
|
Senserrich J, Pauls E, Armand-Ugón M, Clotet-Codina I, Moncunill G, Clotet B, Esté JA.
HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region.
|
| 2008 |
J Pharmacol Exp Ther. 324:558-67 |
|
|
|
Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, Martinez-Picado J.
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
|
| 2008 |
Virus Res. 131:260-70 |
|
|
|
Franco S, Clotet B, Martínez MA.
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
|
| 2008 |
J Antimicrob Chemother. 61:13-6 |
|
|
|
CLotet, B
Once-daily dosing of nevirapine in HAART.
|
| 2008 |
J Antimicrob Chemother. 61:206-9 |
|
|
|
Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
|
| 2008 |
Immunology. Aug 28. [Epub ahead of print] |
|
|
|
Darwich L, Coma G, Peña R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M.
Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.
|
| 2008 |
AIDS. 2008 Aug 20. [Epub ahead of print] |
|
|
|
Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CA, Cooper DA, Schapiro JM.
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
|
| 2008 |
Antimicrob Agents Chemother. 2008 Aug 25. [Epub ahead of print] |
|
|
|
Moltó J, Santos JR, Pérez-Álvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B.
DARUNAVIR INHIBITORY QUOTIENT PREDICTS THE 48-WEEK VIROLOGICAL RESPONSE TO DARUNAVIR-BASED SALVAGE THERAPY IN HIV-INFECTED PROTEASE INHIBITOR-EXPERIENCED PATIENTS.
|
| 2008 |
ChemMedChem. 2008 Jul 31. [Epub ahead of print] |
|
|
|
Pettersson S, Pérez-Nueno VI, Ros-Blanco L, Puig de La Bellacasa R, Rabal MO, Batllori X, Clotet B, Clotet-Codina I, Armand-Ugón M, Esté J, Borrell JI, Teixidó J.
Discovery of Novel Non-Cyclam Polynitrogenated CXCR4 Coreceptor Inhibitors.
|
| 2008 |
J Antimicrob Chemother. 2008 Jul 23. [Epub ahead of print] |
|
|
|
Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B.
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
|
| 2008 |
N Engl J Med. 2008 Jul 24;359(4):355-65. |
|
|
|
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.
Collaborators (120)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
|
| 2008 |
N Engl J Med. 2008 Jul 24;359(4):339-54. |
|
|
|
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.
Collaborators (120)
Raltegravir with optimized background therapy for resistant HIV-1 infection.
|
| 2008 |
Antiviral Res. 2008 Jul 3. [Epub ahead of print] |
|
|
|
Bosch B, Grigorov B, Senserrich J, Clotet B, Darlix JL, Muriaux D, Este JA.
A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission.
|
| 2008 |
J Antimicrob Chemother. 2008 Jun 30. [Epub ahead of print] |
|
|
|
Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B.
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
|
| 2008 |
AIDS. 2008 Jul 11;22(11):1313-22. |
|
|
|
Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C; ORVACS Study Group.
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
|
| 2008 |
Antivir Ther. 2008;13(3):399-407. |
|
|
|
Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM; EuroSIDA Study Group.
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
|
| 2008 |
Clin Infect Dis. 2008 Jul 15;47(2):266-85. |
|
|
|
Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD.
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
|
| 2008 |
HIV Clin Trials. 2008 May-Jun;9(3):177-85. |
|
|
|
Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.
Collaborators (43)
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
|
| 2008 |
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. |
|
|
|
Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group.
Collaborators (175)
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
|
| 2008 |
Antivir Ther. 2008;13(2):231-40. |
|
|
|
Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
|
| 2008 |
HIV Med. 2008 May 13. [Epub ahead of print] |
|
|
|
Llibre J, Bonjoch A, Iribarren J, Galindo M, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B; the HIV Conference Call study group.
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
|
| 2008 |
Top HIV Med. 2008 Mar-Apr;16(1):62-8. |
|
|
|
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the Drug Resistance Mutations in HIV-1: Spring 2008.
|
| 2008 |
Retrovirology. 2008 Mar 31;5:32. |
|
|
|
Puigdomènech I, Massanella M, Izquierdo-Useros N, Ruiz-Hernandez R, Curriu M, Bofill M, Martinez-Picado J, Juan M, Clotet B, Blanco J.
HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4.
|
| 2008 |
HIV Med. 2008 Apr;9(4):221-6. |
|
|
|
De Lazzari E, León A, Arnaiz JA, Martinez E, Knobel H, Negredo E, Clotet B, Montaner J, Storfer S, Asenjo MA, Mallolas J, Miró JM, Gatell JM.
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
|
| 2008 |
AIDS. 2008 Mar 30;22(6):737-40. |
|
|
|
Angus B, Lampe F, Tambussi G, Duvivier C, Katlama C, Youle M, Williams I, Clotet B, Fisher M, Post FA, Babiker A, Phillips A; TILT Trial Steering Committee.
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
|
|
